Drugs dosing in intensive care unit during continuous renal replacement therapy;Adaptation posologique des médicaments couramment utilisés en réanimation lors d'épuration extrarénale continue

Nephrologie et Therapeutique

Volumn 5, Issue 6, 2009, Pages 533-541

  Bourquin, Vincent ^a   Ponte, Belén ^a   Saudan, Patrick ^a   Martin, Pierre Yves ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Continuous renal replacement therapy; Dosing adjustment; Intensive care unit; Pharmacokinetic

Indexed keywords

ACICLOVIR; AMIKACIN; AMIODARONE; AMOXICILLIN; AMPHOTERICIN B; ATENOLOL; CASPOFUNGIN; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; FENTANYL; FLUCONAZOLE; GANCICLOVIR; GENTAMICIN; IMIPENEM; ITRACONAZOLE; LABETALOL; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METOPROLOL; PIPERACILLIN PLUS TAZOBACTAM; PROPOFOL; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ADSORPTION; CONTINUOUS INFUSION; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICAL ILLNESS; DIALYSIS; DIFFUSION; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; KIDNEY INJURY; LIVER DYSFUNCTION; MOLECULAR WEIGHT; MULTIPLE ORGAN FAILURE; PLASMA CLEARANCE; PLASMA PROTEIN BINDING; PRESCRIPTION; SEPSIS; SHORT SURVEY; TISSUE PERFUSION;

DRUG DOSAGE CALCULATIONS; HUMANS; INTENSIVE CARE UNITS; PHARMACOKINETICS; RENAL REPLACEMENT THERAPY;

EID: 71549117931     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2009.02.010     Document Type: Short Survey

References (54)

1. Nosé Y. Inventor for life: Pim Kolff. Artif Organs 31 (2007) 663-664
2. Kramer P., Wigger W., Rieger J., et al. Arteriovenous haemofiltration: a new and simple method for treatment of over-hydrated patients resistant to diuretics. Klin Wochenschr 55 (1977) 1121-1122
3. Kramer P., Wigger W., Matthaei D., et al. Clinical experience with continuously monitored fluid balance in automatic hemofiltration. Artif Organs 2 (1978) 147-149
4. Paganini E.P., and Nakamoto S. Continuous slow ultrafiltration in oliguric acute renal failure. Trans Am Soc Artif Intern Organs 26 (1980) 201-204
5. John S., and Eckardt K.U. Renal replacement strategies in the ICU. Chest 132 (2007) 1379-1388
6. Ronco C., Bellomo R., Homel P., et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356 (2000) 26-30
7. Saudan P., Niederberger M., De Seigneux S., et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney Int 70 (2006) 1312-1317
8. VA/NIH Acute Renal Failure Trial Network, Palevsky P.M., Zhang J.H., et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 359 (2008) 7-20
9. Tolwani A.J., Campbell R.C., Stofan B.S., et al. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol 19 (2008) 1233-1238
10. Kronfol N.O., Lau A.H., and Barakat M.M. Aminoglycoside binding to polyacrylonitrile hemofilter membranes during continuous hemofiltration. ASAIO Trans 33 (1987) 300-303
11. Keller F., Giehl M., Frankewitsch T., et al. Pharmacokinetics and drug dosage adjustment to renal impairment. Nephrol Dial Transplant 10 (1995) 1516-1520
12. Bastien O, Boulieu R. Médicaments et épuration extrarénale. Conférence d'actualisation 1997.
13. Aronoff G.R., Benett W.M., Berns J.S., et al. Drug prescribing in renal failure (2007), American College of Physician
14. Colton C.K., Henderson L.W., Ford C.A., et al. Kinetics of hemodiafiltration. I. In vitro transport characteristics of a hollow-fiber blood ultrafilter. J Lab Clin Med 85 (1975) 355-371
15. Henderson L.W., Colton C.K., and Ford C.A. Kinetics of hemodiafiltration. II. Clinical characterization of a new blood cleansing modality. J Lab Clin Med 85 (1975) 372-391
16. Bouman C.S., van Kan H.J., Koopmans R.P., et al. Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intensive Care Med 32 (2006) 2013-2019
17. Keller F., Böhler J., Czock D., et al. Individualized drug dosage in patients treated with continuous hemofiltration. Kidney Int 72 (1999) S29-S31
18. Keller E. Pharmacokinetics during continuous renal replacement therapy. Int J Artif Organs 19 (1996) 113-117
19. Hudson J.Q., Comstock T.J., and Feldman G.M. Evaluation of an in vitro dialysis system to predict drug removal. Nephrol Dial Transplant 19 (2004) 400-405
20. Böhler J., Donauer J., and Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int (1999) S24-S28
21. Buclin T., Robatel C., and Biollaz J. Prescription médicamenteuse lors d'épuration extrarénale continue : bases pharmacocinétique, revue de la littérature et validation d'une approche prédictive simple. Reanim Urg 7 (1998) 232-252
22. Golper T.A., Wedel S.K., Kaplan A.A., et al. Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Int J Artif Organs 8 (1985) 307-312
23. Bellomo R., McGrath B., and Boyce N. Effect of continuous venovenous hemofiltration with dialysis on hormone and catecholamine clearance in critically ill patients with acute renal failure. Crit Care Med 22 (1994) 833-837
24. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 28 (2004) 497-504
25. Bastani B., and Jamal J.A. Removal of morphine but not fentanyl during haemodialysis. Nephrol Dial Transplant 12 (1997) 2802-2804
26. Joh J., Sila M.K., and Bastani B. Nondialyzability of fentanyl with high-efficiency and high-flux membranes. Anesth Analg 86 (1998) 447
27. Bolon M., Bastien O., Flamens C., et al. Midazolam disposition in patients undergoing continuous venovenous hemodialysis. J Clin Pharmacol 41 (2001) 959-962
28. Nathan N., Debord J., Narcisse F., et al. Pharmacokinetics of propofol and its conjugates after continuous infusion in normal and in renal failure patients: a preliminary study. Acta Anaesthesiol Belg 44 (1993) 77-85
29. Singer M., McNally T., Screaton G., et al. Heparin clearance during continuous veno-venous haemofiltration. Intensive Care Med 20 (1994) 212-215
30. Sombolos K.I., Fragia T.K., Gionanlis L.C., et al. Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study. Int J Clin Pharmacol Ther 46 (2008) 198-203
31. Monchi T. Anticoagulation for acute renal replacement therapy. Reanimation 14 (2005) 551-558
32. Jaumain H., Clapson D., Allavéna M., et al. Pharmacocinétique des anti-infectieux en hémofiltration continue. Presse Med 27 (1998) 1536-1544
33. Kuang D., Verbine A., and Ronco C. Pharmacokinetics and antimicrobial dosing adjustment in critically ill patients during continuous renal replacement therapy. Clin Nephrol 67 (2007) 267-284
34. Trotman R.L., Williamson J.C., Shoemaker D.M., et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 41 (2005) 1159-1166
35. Sonck J., Laureys G., and Verbeelen D. The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant 23 (2008) 966-970
36. Fish D.N., Teitelbaum I., and Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 49 (2005) 2421-2428
37. Valtonen M., Tiula E., Backman J.T., et al. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. JAntimicrob Chemother 45 (2000) 701-704
38. Valtonen M., Tiula E., Takkunen O., et al. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 48 (2001) 881-885
39. Mueller S.C., Majcher-Peszynska J., Hickstein H., et al. Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis. Antimicrob Agents Chemother 46 (2002) 1557-1560
40. van der Werf T.S., Mulder P.O., Zijlstra J.G., et al. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 23 (1997) 873-877
41. Wallis S.C., Mullany D.V., Lipman J., et al. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Intensive Care Med 27 (2001) 665-672
42. Czock D., Hüsig-Linde C., Langhoff A., et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin JAm Soc Nephrol 1 (2006) 1263-1268
43. Malone R.S., Fish D.N., Abraham E., et al. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 45 (2001) 2949-2954
44. Fuhrmann V., Schenk P., Jaeger W., et al. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J Antimicrob Chemother 54 (2004) 780-784
45. Bellmann R., Egger P., Djanani A., et al. Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration. Int J Antimicrob Agents 23 (2004) 80-83
46. Bellmann R., Egger P., Gritsch W., et al. Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration. J Antimicrob Chemother 51 (2003) 671-681
47. Valtonen M., Tiula E., and Neuvonen P.J. Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. J Antimicrob Chemother 40 (1997) 695-700
48. Muhl E., Martens T., Iven H., et al. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 56 (2000) 671-678
49. Robatel C., Rusca M., Padoin C., et al. Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient. JAntimicrob Chemother 54 (2004) 269-270
50. Bleyzac N., Barou P., Massenavette B., et al. Assessment of acyclovir intraindividual pharmacokinetic variability during continuous hemofiltration, continuous hemodiafiltration, and continuous hemodialysis. Ther Drug Monit 21 (1999) 520-525
51. Gando S., Kameue T., Nanzaki S., et al. Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. Crit Care Med 26 (1998) 184-187
52. Brendolan A., D'Intini V., Ricci Z., et al. Pulse high volume hemofiltration. Int J Artif Organs 27 (2004) 398-403
53. Mueller B.A., Pasko D.A., and Sowinski K.M. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs 27 (2003) 808-814
54. Ronco C., Tetta C., Mariano F., et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 27 (2003) 792-801